INS and type 2 diabetes mellitus: Retnakaran and colleagues reported that after the initial improvement in β-cell function achieved with pre-randomisation intensive insulin therapy, GLP-1RA liraglutide induced a robust further enhancement of β-cell function that was sustained for 48 weeks in early T2DM but lost upon cessation of therapy13.